Recent News
- Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS® in the European Economic Area, the United Kingdom, Australia and Brazil
- Teijin Pharma to Launch Japan-market Sales of Abaloparatide Acetate for Osteoporosis
- Stemline Therapeutics Inc. Receives Approval from U.S. FDA for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
- Radius Health’s TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
- European Commission Approves ELADYNOS (Abaloparatide) for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
- Radius Appoints Ed Cinca as Chief Commercial Officer
- Radius’ Abaloparatide Receives Positive CHMP Opinion for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
- Radius Announces Publication of Abaloparatide Phase 3 ATOM Trial Data in the Journal of Bone and Mineral Research
- Radius Appoints Scott Briggs as Chief Executive Officer
- Teijin Pharma Receives Additional Approval in Japan for Abaloparatide Acetate as Treatment for Osteoporosis
- Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
- Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
- Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital